| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| P Pasini, M Musiani, C Russo, P Valenti, G Aicardi, J E Crabtree, M Baraldini, A Rod. Chemiluminescence imaging in bioanalysis. Journal of pharmaceutical and biomedical analysis. vol 18. issue 4-5. 1999-04-13. PMID:9919955. |
a proposed application of the method is a 384 well microtiter format assay for high throughput screening of acetylcholinesterase inhibitors such as tacrine, a drug widely used in the treatment of alzheimer's disease, and two recently developed analogues. |
1999-04-13 |
2023-08-12 |
Not clear |
| J Sáez-Valero, G Sberna, C A McLean, D H Smal. Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease. Journal of neurochemistry. vol 72. issue 4. 1999-04-13. PMID:10098867. |
molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with alzheimer's disease. |
1999-04-13 |
2023-08-12 |
Not clear |
| B P Imbimbo, M Nicoli, C Martini, G P Tomelleri, P Martelli, G P Ferrari, G Gambin. Acetylcholinesterase assay may predict cognitive response of Alzheimer patients to eptastigmine treatment. European journal of clinical pharmacology. vol 54. issue 9-10. 1999-03-26. PMID:9923589. |
acetylcholinesterase assay may predict cognitive response of alzheimer patients to eptastigmine treatment. |
1999-03-26 |
2023-08-12 |
Not clear |
| J E Lachowicz, D Lowe, R A Duffy, V Ruperto, L A Taylor, H Guzik, J Brown, J G Berger, M Tice, R McQuade, J Kozlowski, J Clader, C D Strader, N Murgol. SCH 57790: a novel M2 receptor selective antagonist. Life sciences. vol 64. issue 6-7. 1999-03-25. PMID:10069520. |
as a decrease in cholinergic neurons has been observed in alzheimer's disease (ad), therapeutic approaches to ad include inhibition of acetylcholinesterase to increase acetylcholine levels. |
1999-03-25 |
2023-08-12 |
human |
| F Giubilei, S Strano, B P Imbimbo, P Tisei, G Calcagnini, S Lino, M Frontoni, M Santini, C Fiesch. Cardiac autonomic dysfunction in patients with Alzheimer disease: possible pathogenetic mechanisms. Alzheimer disease and associated disorders. vol 12. issue 4. 1999-03-18. PMID:9876965. |
we studied a possible correlation between autonomic cardiac activity and the level of the red blood cell acetylcholinesterase (ache) in patients with probable alzheimer disease (ad). |
1999-03-18 |
2023-08-12 |
Not clear |
| J Patock. Huperzine A--an interesting anticholinesterase compound from the Chinese herbal medicine. Acta medica (Hradec Kralove). vol 41. issue 4. 1999-02-25. PMID:9951045. |
huperzine a is a strong inhibitor of cholinesterases with high selectivity to acetylcholinesterase and in china is developed as therapeutic against alzheimer's disease. |
1999-02-25 |
2023-08-12 |
Not clear |
| C M Spencer, S Nobl. Rivastigmine. A review of its use in Alzheimer's disease. Drugs & aging. vol 13. issue 5. 1999-02-12. PMID:9829166. |
rivastigmine (sdz ena 713) is a carbamylating, long-acting reversible and noncompetitive carbamate acetylcholinesterase inhibitor that is indicated as an oral treatment for patients with mild to moderately severe alzheimer's disease. |
1999-02-12 |
2023-08-12 |
Not clear |
| S L Rogers, L T Friedhof. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. British journal of clinical pharmacology. vol 46 Suppl 1. 1999-01-28. PMID:9839758. |
the aim of this study was to characterize the pharmacokinetic and pharmacodynamic profile of donepezil hcl, a chemically distinct and specific acetylcholinesterase (ache) inhibitor for the treatment of alzheimer's disease, following administration of single oral doses. |
1999-01-28 |
2023-08-12 |
Not clear |
| S L Rogers, N M Cooper, R Sukovaty, J E Pederson, J N Lee, L T Friedhof. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. British journal of clinical pharmacology. vol 46 Suppl 1. 1999-01-28. PMID:9839759. |
the aim of this study was to characterize the pharmacokinetics and pharmacodynamics of donepezil hcl, a new, chemically distinct and specific acetylcholinesterase (ache) inhibitor for the treatment of alzheimer's disease, following multiple-dose administration. |
1999-01-28 |
2023-08-12 |
Not clear |
| A B Bonnefont, F J Muñoz, N C Inestros. Estrogen protects neuronal cells from the cytotoxicity induced by acetylcholinesterase-amyloid complexes. FEBS letters. vol 441. issue 2. 1999-01-22. PMID:9883888. |
the senile plaques present in alzheimer's disease (ad) are composed of a core of amyloid beta-peptide (abeta) plus several proteins including acetylcholinesterase (ache). |
1999-01-22 |
2023-08-12 |
mouse |
| S L Roger. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil. Dementia and geriatric cognitive disorders. vol 9 Suppl 3. 1999-01-21. PMID:9853200. |
donepezil hci is a piperidine-based reversible acetylcholinesterase (ache) inhibitor, chemically distinct from other cholinesterase (che) inhibitors and rationally designed to treat the symptoms of alzheimer's disease (ad). |
1999-01-21 |
2023-08-12 |
human |
| V Jelic, T Dierks, K Amberla, O Almkvist, B Winblad, A Nordber. Longitudinal changes in quantitative EEG during long-term tacrine treatment of patients with Alzheimer's disease. Neuroscience letters. vol 254. issue 2. 1999-01-08. PMID:9779926. |
quantitative eeg is a potentially useful tool in demonstrating the effects of treatments with acetylcholinesterase (ache) inhibitors on the progression of alzheimer's disease (ad). |
1999-01-08 |
2023-08-12 |
Not clear |
| N C Inestrosa, R Alarcó. Molecular interactions of acetylcholinesterase with senile plaques. Journal of physiology, Paris. vol 92. issue 5-6. 1999-01-08. PMID:9789834. |
acetylcholinesterase (ache) present in alzheimer plaques is resistant to low ph, anti-che inhibitors and high substrate concentrations in comparison with the free enzyme. |
1999-01-08 |
2023-08-12 |
Not clear |
| F L Tse, R Laplanch. Absorption, metabolism, and disposition of [14C]SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration. Pharmaceutical research. vol 15. issue 10. 1998-12-24. PMID:9794506. |
sdz ena 713 (rivastigmine) is an acetylcholinesterase inhibitor intended for therapeutic use in alzheimer's disease. |
1998-12-24 |
2023-08-12 |
Not clear |
| L T Piecoro, D P Wermeling, F A Schmitt, J W Ashfor. Seizures in patients receiving concomitant antimuscarinics and acetylcholinesterase inhibitor. Pharmacotherapy. vol 18. issue 5. 1998-12-09. PMID:9758325. |
seizures occurred in two patients with probable alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor. |
1998-12-09 |
2023-08-12 |
Not clear |
| L T Piecoro, D P Wermeling, F A Schmitt, J W Ashfor. Seizures in patients receiving concomitant antimuscarinics and acetylcholinesterase inhibitor. Pharmacotherapy. vol 18. issue 5. 1998-12-09. PMID:9758325. |
with increasing administration of acetylcholinesterase inhibitors for patients with alzheimer's disease, practitioners should be aware of the potential for drug-drug interactions and other complications. |
1998-12-09 |
2023-08-12 |
Not clear |
| C Melchiorre, V Andrisano, M L Bolognesi, R Budriesi, A Cavalli, V Cavrini, M Rosini, V Tumiatti, M Recanatin. Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. Journal of medicinal chemistry. vol 41. issue 22. 1998-11-23. PMID:9784091. |
acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against alzheimer's disease. |
1998-11-23 |
2023-08-12 |
Not clear |
| R J Polinsk. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clinical therapeutics. vol 20. issue 4. 1998-11-18. PMID:9737824. |
clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of alzheimer's disease. |
1998-11-18 |
2023-08-12 |
human |
| M Grundman, J Corey-Bloom, L J Tha. Perspectives in clinical Alzheimer's disease research and the development of antidementia drugs. Journal of neural transmission. Supplementum. vol 53. 1998-11-12. PMID:9700663. |
current treatment approaches in alzheimer's disease are primarily symptomatic, with the major therapeutic strategy based on acetylcholinesterase inhibition. |
1998-11-12 |
2023-08-12 |
Not clear |
| I G McKeit. The clinical trial protocol of the Metrifonate in Alzheimer's Trial (MALT). Dementia and geriatric cognitive disorders. vol 9 Suppl 2. 1998-11-06. PMID:9718228. |
the promising results of early trials in alzheimer's disease with the acetylcholinesterase inhibitor metrifonate prompted initiation of the metrifonate in alzheimer's trial (malt). |
1998-11-06 |
2023-08-12 |
Not clear |